Genrix Bio's clinical trial application for the research product GR2301 injection has been approved
I'm PortAI, I can summarize articles.
Genrix Bio announced that its clinical trial application for the investigational product GR2301 injection has been approved by the National Medical Products Administration. GR2301 is a recombinant fully human anti-IL-15 monoclonal antibody designed to treat autoimmune diseases such as vitiligo caused by dysregulation of IL-15 expression
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments